Hereditary sensory and autonomic neuropathy type 7
Also known as CIP with hyperhidrosis and gastrointestinal dysfunction, HSAN VII, HSAN with hyperhidrosis and gastrointestinal dysfunction, HSAN7+9 more
CIP with hyperhidrosis and gastrointestinal dysfunction, HSAN VII, HSAN with hyperhidrosis and gastrointestinal dysfunction, HSAN7, SCN11A autosomal dominant hereditary sensory and autonomic neuropathy, autosomal dominant hereditary sensory and autonomic neuropathy caused by mutation in SCN11A, congenital insensitivity to pain with hyperhidrosis and gastrointestinal dysfunction, hereditary sensory and autonomic neuropathy type VII, hereditary sensory and autonomic neuropathy with hyperhidrosis and gastrointestinal dysfunction, HSAN 7, insensitivity to pain, congenital, with gastrointestinal dysfunction and hyperhidrosis, neuropathy, hereditary sensory and autonomic, type 7, neuropathy, hereditary sensory and autonomic, type VII.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q2 2027.
- Q2 2027A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Sham Injection Evaluation for Post COVID Condition: the CeASE RCT
- Q2 2027Comparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.
- Q4 2027A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty
- Q1 2028A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes Mellitus
- Q3 2030Efficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled Trial
Clinical MilestonesView all 10Hide
- 2026-06-08A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Sham Injection Evaluation for Post COVID Condition: the CeASE RCTResults expected Q2 2027
- 2026-06-03A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip ArthroplastyResults expected Q4 2027
- 2026-04-30A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes MellitusResults expected Q1 2028
- 2026-03-25Comparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.Results expected Q2 2027
- 2025-10-24Efficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled TrialResults expected Q3 2030
- 2026-05-12Efficacy and Safety of Topical Lidocaine 23%/Tetracaine 7% Ointment Versus Placebo for Post-Hemorrhoidectomy Pain: A Double-Blind Randomized Controlled TrialCompleted
- 2025-10-29Effect of Virtual Reality Distraction in Reducing Patients' Pain and Anxiety During Peripheral Arterial Angioplasty: a Randomized Prospective StudyCompleted
- 2025-10-15Efficacy and Safety of Etoricoxib 90 mg + Diacerein 50 mg Capsule Compared to Meloxicam 15 mg + Diacerein 50 mg in Patients With Knee and/or Hip Osteoarthritis: A Phase III, Controlled, Randomized, Double-blind, Multicenter Clinical Trial.Completed
- 2027-12-01Guard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25Withdrawn
- 2026-02-26Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy: A Randomized Controlled TrialTerminated
- 2027-12-01ClinicalGuard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25Withdrawn
- 2026-06-08ClinicalA Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Sham Injection Evaluation for Post COVID Condition: the CeASE RCTResults expected Q2 2027
- 2026-06-03ClinicalA Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip ArthroplastyResults expected Q4 2027
- 2026-05-12ClinicalEfficacy and Safety of Topical Lidocaine 23%/Tetracaine 7% Ointment Versus Placebo for Post-Hemorrhoidectomy Pain: A Double-Blind Randomized Controlled TrialCompleted
- 2026-04-30ClinicalA Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes MellitusResults expected Q1 2028
- 2026-03-25ClinicalComparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.Results expected Q2 2027
- 2026-02-26ClinicalOpioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy: A Randomized Controlled TrialTerminated
- 2025-10-29ClinicalEffect of Virtual Reality Distraction in Reducing Patients' Pain and Anxiety During Peripheral Arterial Angioplasty: a Randomized Prospective StudyCompleted
- 2025-10-24ClinicalEfficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled TrialResults expected Q3 2030
- 2025-10-15ClinicalEfficacy and Safety of Etoricoxib 90 mg + Diacerein 50 mg Capsule Compared to Meloxicam 15 mg + Diacerein 50 mg in Patients With Knee and/or Hip Osteoarthritis: A Phase III, Controlled, Randomized, Double-blind, Multicenter Clinical Trial.Completed
Clinical trials
The current development programme across all trial phases.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
CIP with hyperhidrosis and gastrointestinal dysfunction, HSAN VII, HSAN with hyperhidrosis and gastrointestinal dysfunction, HSAN7, SCN11A autosomal dominant hereditary sensory and autonomic neuropathy, autosomal dominant hereditary sensory and autonomic neuropathy caused by mutation in SCN11A, congenital insensitivity to pain with hyperhidrosis and gastrointestinal dysfunction, hereditary sensory and autonomic neuropathy type VII, hereditary sensory and autonomic neuropathy with hyperhidrosis and gastrointestinal dysfunction, HSAN 7, insensitivity to pain, congenital, with gastrointestinal dysfunction and hyperhidrosis, neuropathy, hereditary sensory and autonomic, type 7, neuropathy, hereditary sensory and autonomic, type VII
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.